TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26927501
Drug: NA (5
Normalized name: Cianocobalamina (57 Co)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA (5 mg/d) with CEE (0.625 mg/d)
Study: 26927501
Drug: NA (5
Normalized name: Cianocobalamina (57 Co)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA (5 mg/d) with placebo
Study: 21757823
Drug: hANP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: hANP group (100 μg bolus injection of hANP)
Study: 21757823
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (physiological saline injection)
Study: 19242495
Drug: Cladribine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine (9 mg/m² per dose) and cytarabine (500 mg/m² per day) - arm B
Study: 19242495
Drug: Cladribine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine (9 mg/m² per dose) and cytarabine (500 mg/m² per dose) - arm A
Study: 9354205
Drug: ACT-10 (amoxycillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-10 (amoxycillin 1000 mg b.d. + clarithromycin 500 mg b.d. + omeprazole 20 mg daily for 10 days)
Study: 9354205
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (clarithromycin 500 mg t.d.s. + omeprazole 40 mg daily for 14 days)
Study: 20363510
Drug: Oseltamivir (2mg/kg)
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oseltamivir (2mg/kg) given twice daily for 5 days
Study: 17554248
Drug: Green tea-extract
Normalized name: green tea extract
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea-extract powder supplementation (544 mg polyphenols, 456 mg catechins daily for 2 months)
Study: 1958394
Drug: Cinnarizine 3
Normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 3 x 75 mg
Study: 6412638
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg capsule of powdered sodium cromoglycate delivered by turbo inhaler (spinhaler)
Study: 6412638
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of aerosolised sodium cromoglycate delivered by pressurised cannister inhaler (aerosol)
Study: 31383853
Drug: Psychopharmacological and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological and psychotherapeutic treatment in MARS study
Study: 28626220
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 500 μg subcutaneously every 3 weeks for 24 weeks
Study: 27433865
Drug: Dance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance therapy (3 sessions weekly for 2 months)
Study: 27433865
Drug: Self-care treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-care treatment advice (control group)
Study: 19158002
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol colonoscopy-like preparation
Study: 11990913
Drug: Dexanabinol (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexanabinol (48 or 150 mg)
Study: 11990913
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 or 3 mL vehicle)
Study: 9641187
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 4 IU/m2/day for 6 months
Study: 8120654
Drug: Low fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fiber diet (15 g total dietary fiber/d)
Study: 8120654
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with 62 g/d of brewer's spent grain
Study: 947448
Drug: Specially designed
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specially designed stretcher suspension system
Study: 31919523
Drug: Low-magnitude contingency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-magnitude contingency management (CM-L)
Study: 23945447
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (30 mg/d, 50 mg/d, or 70 mg/d)
Study: 18280042
Drug: Scopolamine (cholinergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (cholinergic antagonist)
Study: 20102786
Drug: Pharmacological-induced menopause
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological-induced menopause (GnRHa treatment)
Study: 11307807
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (OA)
Study: 8300811
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone 12 IU/day
Study: 3570862
Drug: 650 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 micrograms daily vitamin A supplement
Study: 2568777
Drug: 0.75 ml
Normalized name: ethanol 0.75 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml iopromide/kg body weight
Study: 2568777
Drug: 1.0 ml
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml iopromide/kg body weight
Study: 2568777
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml iopromide/kg body weight
Study: 2568777
Drug: 2.0 ml
Normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 ml iopromide/kg body weight
Study: 18159577
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine administration
Study: 23833309
Drug: Temozolomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2))
Study: 23833309
Drug: High-dose IFN-α2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN-α2b (HDI)
Study: 16755435
Drug: MBO model
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBO model of treatment (experimental group U[+])
Study: 16755435
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment (control group K[+])
Study: 10474470
Drug: Topical 60%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 60% DMSO applied before each filling session
Study: 8627841
Drug: Followed without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Followed without any treatment
Study: 1763406
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (7.5 Gy point A dose)
Study: 1763406
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (6 Gy point A dose)
Study: 3539037
Drug: Gold therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold therapy
Study: 28394361
Drug: Walnut oil
Normalized name: Walnut oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut oil (15 cc daily for 90 days)
Study: 21704493
Drug: Sham (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham (24 mg)
Study: 16547328
Drug: Topical ciclosporin
Normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical ciclosporin A 0.05%
Study: 14723265
Drug: Conventional antiepileptic
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antiepileptic agents (phenytoin, phenobarbital, carbamazepine, valproic acid)
Study: 11232180
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy for severe acute alcoholic hepatitis
Study: 1597912
Drug: Betacarotene as
Normalized name: betacarotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betacarotene as a possible skin cancer preventive agent
Study: 6689670
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture (L‐phenylalanine, L‐tryptophan) infused intraduodenally at increasing rates (0.2, 0.8, and 3.2 ml X min‐1)
Study: 6689670
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infused into the intestine at increasing rates (0.2, 0.8, and 3.2 ml X min‐1)
Study: 6689670
Drug: Mannitol solutions
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol solutions of increasing osmolality (370, 520, and 700 mosmol X kg‐1) infused into the duodenum at 0.2 ml X min‐1
Study: 6689670
Drug: Atropine infusion
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine infusion (20 micrograms X kg‐1 X h‐1)
Study: 31483549
Drug: Proactive outreach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive outreach intervention (mailed invitation and telephone calls, free cessation treatment including nicotine replacement therapy and intensive telephone counseling)
Study: 30004139
Drug: MOUTh (Managing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOUTh (Managing Oral Hygiene Using Threat Reduction)
Study: 25414155
Drug: Liraglutide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.6 mg single dose, titrated to 1.8 mg after 21 days)
Study: 9424967
Drug: Psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatment (Group I)
Study: 9424967
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg/kg orally (Group II)
Study: 8462805
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (4 g per day intravenously for 7 days)
Study: 30238574
Drug: Intravenous acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetazolamide at a dose of 500 mg once daily
Study: 26504153
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg) plus prednisone (5 mg)
Study: 26504153
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg) plus exemestane (25 mg)
Study: 26098476
Drug: n-3 LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 LCPUFA (1.2 g EPA/DHA/day), n=85
Study: 18270575
Drug: HAMS‐ORS (hypo‐osmolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAMS‐ORS (hypo‐osmolar ORS with amylase resistant high amylose maize starch 50g/L)
Study: 15743422
Drug: Emdogain Gel
Normalized name: Memogain
DrugBank: Benzgalantamine (DB19353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emdogain Gel (EMDgel)
Study: 14692305
Drug: Tibolone 5
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 5 mg/day
Study: 14692305
Drug: ECE/MPA (equine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECE/MPA (equine conjugated estrogens 0.625 mg + medroxyprogesterone acetate 2.5 mg/day)
Study: 10820349
Drug: 1% 5-aminolevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% 5-aminolevulinic acid (5-ALA) topical application after 60-90 minutes
Study: 781882
Drug: Penicillin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (20 mega-units daily)
Study: 30407276
Drug: ABT (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT (135 mL of RBC)
Study: 30407276
Drug: ABT (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT (combined 135 mL and 235 mL of RBC)
Study: 28623895
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise therapy (Ex group: 18 subjects) - brisk walking for 30 min per day for 12 months
Study: 28623895
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C group: 18 subjects) - no exercise therapy guidance, only recorded daily steps
Study: 25631224
Drug: Monthly regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly regular didactic lecture (Group 2)
Study: 25631224
Drug: Monthly interactive
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly interactive education workshop (Group 3)
Study: 16634995
Drug: Fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril 20 mg daily
Study: 10962547
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone (HD MP)
Study: 9169953
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day beta-carotene in enteral feeding
Study: 3992070
Drug: Hay fever
Normalized name: Hay-Crom Hay Fever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hay fever treatments (specific treatments not detailed)
Study: 29265566
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ropivacaine 0.2%
Study: 26067286
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment plus respiratory physiotherapy for 3 weeks
Study: 12386351
Drug: Uterine balloon
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uterine balloon therapy (UBT)
Study: 9918905
Drug: Tauroursodeoxycholate (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholate (750 mg/d for 2 months)
Study: 9918905
Drug: Ursodeoxycholate (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholate (750 mg/d for 2 months)
Study: 1859038
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate in saline (AS/S) nasal spray
Study: 25211927
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy including local negative pressure and laser illumination (LLNP)
Study: 25211927
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with LLNP
Study: 25211927
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LLNP with PDE5 inhibitors
Study: 30442259
Drug: Post-therapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-therapy
Study: 9925136
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus BG2FO4, ingested twice per day for 7 days
Study: 8583783
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (48 pmol/kg/min for 15 min)
Study: 2197347
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin
Study: 510213
Drug: Prazosin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (20 mg/d)
Study: 27712970
Drug: Statistical model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical model for protamine titration
Study: 27712970
Drug: Fixed protamine‐heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed protamine‐heparin dose ratio (1:1)
Study: 14981605
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/d orally)
Study: 11180005
Drug: Suberythemal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suberythemal dose of whole body irradiation from ultraviolet-A-emitting fluorescent tubes
Study: 9589815
Drug: Foscarnet (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (four doses)
Study: 9589815
Drug: Zalcitabine (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalcitabine (five doses)
Study: 9589815
Drug: Concomitant foscarnet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant foscarnet (four doses) and zalcitabine (six doses)
Study: 7920609
Drug: Pulse cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse cyclophosphamide (0.5‐1.0 g/m2 body surface area) for 4 months, followed by bimonthly doses for 4 months and quarterly doses for 6 months
Study: 7920609
Drug: Pulse methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulse methylprednisolone (10‐20 mg/kg weight) initially for 3 consecutive days and thereafter in the same intervals as cyclophosphamide
Study: 23994192
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (2mA, 30-min, 10-daily sessions and two additional fortnight sessions)
Study: 23731168
Drug: Silodosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin (8 mg/day, n=53)
Study: 23731168
Drug: Naftopidil (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil (75 mg/day, n=44)
Study: 16316872
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (200 to 1600 microg/d via pressurized metered-dose inhaler)
Study: 1929311
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) once daily for 3 days
Study: 1929311
Drug: Trimethoprim-sulfamethoxazole (160:800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160:800 mg) twice daily for 7 days
Study: 6357014
Drug: Ethanol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.5 ml/kg, p.o.)
Study: 30579860
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bleaching treatment, G1 and G4)
Study: 28176424
Drug: PAP-guided HF
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hyco-pap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP-guided HF therapy using the CardioMEMS™ HF system
Study: 28176424
Drug: PAP-guided HF
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hyco-pap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP-guided HF therapy using the CardioMEMS™ HF system with estimated staff time included
Study: 15372416
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (IVAA) 100 mg after each dialysis session
Study: 11472293
Drug: Epidural washout
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural washout with twice the volume of 2% mepivacaine (group 2x)
Study: 7851275
Drug: bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate 400 mg/day for 4 weeks
Study: 27014755
Drug: Coffee +
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee + polyethylene glycol + ascorbic acid (750 mL, twice)
Study: 27014755
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol + ascorbic acid (1-L, twice)
Study: 18095148
Drug: rhuEpo targeting
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuEpo targeting at Hb >= 13.0 g/dL
Study: 26557787
Drug: Sleep restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep restriction therapy
Study: 9847656
Drug: Preemptive lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive lumbar epidural morphine (2 to 4 mg during anesthetic induction)
Study: 9847656
Drug: Postincisional lumbar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postincisional lumbar epidural morphine (2 to 4 mg upon excision of tissue)
Study: 7859638
Drug: Gm phenotype
Normalized name: Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype
DrugBank: DCP-001 (DB17423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gm phenotype of g and gft
Study: 29068592
Drug: Crocin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (30 mg per day for 8 weeks)
Study: 8853725
Drug: Recreational drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational drug use
Study: 8236402
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg for 30 days
Study: 8236402
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg for 15 days
Study: 8236402
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg for 30 days
Study: 8236402
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg for 30 days and 20 mg/kg for 15 days
Study: 3122247
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg oral dose)
Study: 3122247
Drug: Cocaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.2 mg/kg IV injection)
Study: 28855345
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment (IAT) plus usual care
Study: 27501767
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus paclitaxel (bevacizumab 10 mg/kg on days 1 and 15 plus paclitaxel 90 mg/m² on days 1, 8, and 15 every 4 weeks)
Study: 27501767
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus capecitabine (bevacizumab 15 mg/kg on day 1 plus capecitabine 1000 mg/m² twice daily on days 1-14 every 3 weeks)
Study: 24477043
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (PRT) combined with a protein-enriched diet facilitated through lean red meat (∼160 g cooked, 6 days/week)